Aligos Therapeutics (ALGS) Current Leases (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Current Leases for 8 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases fell 9.99% year-over-year to $3.2 million; the trailing twelve-month figure through Jun 2026 stood at $3.2 million (down 9.99% YoY), and the FY2025 full-year result was $3.6 million, up 4.62% from the prior year.
• Current Leases eased to $3.2 million in Q2 2026 per ALGS's latest filing, from $3.6 million in the prior quarter.
• Across five years, Current Leases topped out at $3.6 million in Q1 2026 and bottomed at $2.8 million in Q2 2022.
• Historically, Current Leases has averaged $3.3 million across 5 years, with a median of $3.2 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Current Leases rose 25.68% in 2022, then dropped 9.99% in 2026.
• Over 5 years, Current Leases stood at $3.0 million in 2022, then rose by 6.39% to $3.2 million in 2023, then advanced by 5.98% to $3.4 million in 2024, then advanced by 4.62% to $3.6 million in 2025, then fell by 11.96% to $3.2 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $3.2 million, $3.6 million, and $3.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.